146 related articles for article (PubMed ID: 37479587)
21. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
[TBL] [Abstract][Full Text] [Related]
22. Outcomes After Surgical Resection of Early-stage Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations.
Chow OS; Villena-Vargas J; Nasar A; Sun B; Harrison S; Lee B; Port JL; Altorki NK; Stiles BM
Ann Thorac Surg; 2022 Sep; 114(3):905-910. PubMed ID: 34454901
[TBL] [Abstract][Full Text] [Related]
23. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
Xu L; Guo R
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
Kaseda K; Asakura K; Kazama A; Ozawa Y
Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
Renaud S; Seitlinger J; Guerrera F; Reeb J; Beau-Faller M; Voegeli AC; Siat J; Clément-Duchêne C; Tiotiu A; Santelmo N; Costardi L; Ruffini E; Falcoz PE; Vignaud JM; Massard G
Ann Surg Oncol; 2018 Apr; 25(4):1069-1078. PubMed ID: 29362963
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
[TBL] [Abstract][Full Text] [Related]
28. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.
Liu Y; Kim J; Balagurunathan Y; Li Q; Garcia AL; Stringfield O; Ye Z; Gillies RJ
Clin Lung Cancer; 2016 Sep; 17(5):441-448.e6. PubMed ID: 27017476
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.
Kamigaichi A; Mimae T; Tsubokawa N; Miyata Y; Adachi H; Shimada Y; Ito H; Ikeda N; Okada M
Ann Thorac Surg; 2024 Apr; 117(4):743-751. PubMed ID: 36739066
[TBL] [Abstract][Full Text] [Related]
30. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
[TBL] [Abstract][Full Text] [Related]
31. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma.
Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X
Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101
[TBL] [Abstract][Full Text] [Related]
33. The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Yim JJ; Chung DH; Yoo CG; Kim YW; Han SK; Park YS
PLoS One; 2016; 11(11):e0166821. PubMed ID: 27861565
[TBL] [Abstract][Full Text] [Related]
34. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
[TBL] [Abstract][Full Text] [Related]
35. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K
Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
37. Clinical usefulness of the 3-tier classification according to the proportion of morphological patterns for patients with pathological stage I invasive lung adenocarcinoma.
Osawa J; Shimada Y; Maehara S; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Matsubayashi J; Ikeda N
Gen Thorac Cardiovasc Surg; 2021 Jun; 69(6):943-949. PubMed ID: 33385289
[TBL] [Abstract][Full Text] [Related]
38. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
[TBL] [Abstract][Full Text] [Related]
39. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Yoshiya T; Kai Y; Tsutani Y; Mimura T; Konishi K; Takeshima Y; Okada M
Thorac Cancer; 2018 Dec; 9(12):1594-1602. PubMed ID: 30298562
[TBL] [Abstract][Full Text] [Related]
40. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
